Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marcelo Pitombeira de Lacerda, Meletios Athanasios Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther Gonzalez, Chang-Ki Min, Anna Sureda, Ivan Spicka, Pawel Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vania Hungria, Meral Beksac
Institutions: Universidade da Região de Joinville, National and Kapodistrian University of Athens, University Hospital Brno, Samsung Medical Center, Sungkyunkwan University, Russian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency, Hospital Universitario De Cabueñes, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Institut Català d'Oncologia, Universitat de Barcelona, Charles University, General University Hospital in Prague, Medical University of Lublin, Botkin Hospital, North Shore Hospital, Waitemata District Health Board, GlaxoSmithKline (India), GlaxoSmithKline (United States), GlaxoSmithKline Research & Development Limited (United Kingdom), São Germano Oncologia, Istinye University, Liv Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809760